377. Phase I trial of two novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as 4th dose boosters

BACKGROUND: SARS-CoV-2 booster vaccination needs to enhance protection against variants and minimise immune imprinting. The beta variant drove broad immunity against other SARS-CoV-2 variants, including omicron. We developed 2 vaccines targeting the beta variant receptor-binding domain (RBD): a reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Terry, Deliyannis, Georgia, Braat, Sabine, Allen, Lilith, Audsley, Jennifer, Ciula, Marcin, Giles, Michelle, Griffith, Maryanne, Gherardin, Nicholas, Gordon, Tom, Grimley, Samantha, Horng, Lana, Jackson, David, Juno, Jennifer, Kedzierska, Katherine, Kent, Stephen, Lewin, Sharon, Littlejohn, Mason, McQuilten, Hayley, Mordant, Francesca, Nguyen, Oanh, Soo, Vanessa Pac, Price, Briony, Purcell, Damian, Ramanathan, Pradhipa, Rockman, Steven, Ruan, Zheng, Sasadeusz, Joseph, Simpson, Julie, Subbarao, Kanta, Tan, Chee Wah, Torresi, Joseph, Wang, Jing Jing, Wang, Linfa, Al Wassiti, Harry, Wong, Chinn Yi, Pouton, Colin, Godfrey, Dale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677933/
http://dx.doi.org/10.1093/ofid/ofad500.447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677933/
http://dx.doi.org/10.1093/ofid/ofad500.447

Ejemplares similares